TY - JOUR
T1 - Radiation-associated lens changes in the cardiac catheterization laboratory
T2 - Results from the IC-CATARACT (CATaracts Attributed to RAdiation in the CaTh lab) study
AU - Karatasakis, Aris
AU - Brilakis, Harilaos S.
AU - Danek, Barbara A.
AU - Karacsonyi, Judit
AU - Martinez-Parachini, Jose Roberto
AU - Nguyen-Trong, Phuong Khanh J.
AU - Alame, Aya J.
AU - Roesle, Michele K.
AU - Rangan, Bavana V.
AU - Rosenfield, Kenneth
AU - Mehran, Roxana
AU - Mahmud, Ehtisham
AU - Chambers, Charles E.
AU - Banerjee, Subhash
AU - Brilakis, Emmanouil S.
N1 - Funding Information:
Funding for the study was provided by the Dallas VA Research Corporation. Dr. Karatasakis: none Dr. Danek: none Dr. HS Brilakis: none Dr. Karacsonyi: none Ms. Alame: none Dr. Martinez-Parachini: none Dr. Nguyen-Trong: none Ms. Roesle: none Dr. Rangan: none Dr. Rosenfield: consultant/scientific advisory board member for Abbott Vascular, Cardinal Health, Inari Medical, InspireMD, Surmodics, and Volcano/Philips; consultant/scientific advisory board member with equity or stock options for Capture Vascular, Contego, CRUZAR Systems, Endospan, Eximo, MD Insider, Micell, Shockwave, Silk Road Medical, and Valcare; personal equity in CardioMEMs, Contego, CRUZAR Systems, Embolitech, Icon, Janacare, MD Insider, Primacea, and PQ Bypass; research or fellowship support from Abbott Vascular, Atrium, the National Institutes of Health, and Lutonix-Bard; board member of VIVA Physicians Dr. Mehran: Research Grant Support from Eli Lilly, AstraZeneca, The Medicines Company, BMS/Sanofi-Aventis. Consulting: AstraZeneca, Bayer, CSL Behring, Janssen Pharmaceuticals Inc., Merck & Co., Osprey Medical Inc., Watermark Research Partners. Scientific Advisory Board member for Abbott Laboratories, Boston Scientific Corporation, Covidien, Janssen Pharmaceuticals, The Medicines Company and Sanofi-Aventis Dr. Mahmud: clinical trial support from Boston Scientific, Corinudus, and Gilead; consultant for The Medicines Company; speakers' bureau of Medtronic Dr. Chambers: None Dr. Banerjee: research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Medtronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel. Dr. ES Brilakis: consulting/speaker honoraria from Abbott Vascular, Amgen, Asahi, Elsevier, GE Healthcare and Medicure; research support from Boston Scientific and InfraRedx; spouse is employee of Medtronic.
Funding Information:
Funding for the study was provided by the Dallas VA Research Corporation. Dr. Karatasakis: none Dr. Danek: none Dr. HS Brilakis: none Dr. Karacsonyi: none Ms. Alame: none Dr. Martinez-Parachini: none Dr. Nguyen-Trong: none Ms. Roesle: none Dr. Rangan: none Dr. Rosenfield: consultant/scientific advisory board member for Abbott Vascular, Cardinal Health, Inari Medical, InspireMD, Surmod-ics, and Volcano/Philips; consultant/scientific advisory board member with equity or stock options for Capture Vascular, Contego, CRUZAR Systems, Endospan, Eximo, MD Insider, Micell, Shockwave, Silk Road Medical, and Valcare; personal equity in CardioMEMs, Contego, CRUZAR Systems, Embolitech, Icon, Janacare, MD Insider, Primacea, and PQ Bypass; research or fellowship support from Abbott Vascular, Atrium, the National Institutes of Health, and Lutonix-Bard; board member of VIVA Physicians Dr. Mehran: Research Grant Support from Eli Lilly, AstraZeneca, The Medicines Company, BMS/Sanofi-Aventis. Consulting: AstraZe-neca, Bayer, CSL Behring, Janssen Pharmaceuticals Inc., Merck & Co., Osprey Medical Inc., Watermark Research Partners. Scientific Advisory Board member for Abbott Laboratories, Boston Scientific Corporation, Covidien, Janssen Pharmaceuticals, The Medicines Company and Sanofi-Aventis Dr. Mahmud: clinical trial support from Boston Scientific, Corinu-dus, and Gilead; consultant for The Medicines Company; speakers’ bureau of Medtronic Dr. Chambers: None Dr. Banerjee: research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Med-tronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel.
Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Objective: To examine the relationship between occupational exposure to ionizing radiation and the prevalence of lens changes in interventional cardiologists (ICs) and catheterization laboratory (“cath-lab”) staff. Background: Exposure to ionizing radiation is associated with the development of lens opacities. ICs and cath-lab staff can receive high doses of ionizing radiation without protection, and may thus be at risk for lens opacity formation. Methods: We conducted a cross-sectional study at an interventional cardiology conference. Study participants completed a questionnaire pertaining to occupational exposure to radiation and potential confounders for the development of cataracts, followed by slit-lamp examination and grading of lens findings. Results: A total of 117 attendees participated in the study, including 99 (85%; 49 ± 11 years-old; 82% male) with occupational exposure to ionizing radiation and 18 (15%; 39 ± 12 years-old; 61% male) unexposed controls. The prevalence of overall cortical and posterior subcapsular lens changes (including subclinical findings) was higher in exposed participants compared with controls (47 vs. 17%, P = 0.015). Occupational exposure and age over 60 were independent predictors of lens changes (odds ratio [95% CI]: 6.07 [1.38–43.45] and 7.72 [1.60–43.34], respectively). The prevalence of frank opacities was low and similar between the two groups (14 vs. 6%, P = 0.461). Most lens findings consisted of subclinical changes in the periphery of the lens without impact on visual acuity. Conclusions: Compared with unexposed controls, ICs and cath-lab staff had a higher prevalence of lens changes that may be attributable to ionizing radiation exposure. While most of these changes were subclinical, they are important due to the potential to progress to clinical symptoms, highlighting the importance of minimizing staff radiation exposure.
AB - Objective: To examine the relationship between occupational exposure to ionizing radiation and the prevalence of lens changes in interventional cardiologists (ICs) and catheterization laboratory (“cath-lab”) staff. Background: Exposure to ionizing radiation is associated with the development of lens opacities. ICs and cath-lab staff can receive high doses of ionizing radiation without protection, and may thus be at risk for lens opacity formation. Methods: We conducted a cross-sectional study at an interventional cardiology conference. Study participants completed a questionnaire pertaining to occupational exposure to radiation and potential confounders for the development of cataracts, followed by slit-lamp examination and grading of lens findings. Results: A total of 117 attendees participated in the study, including 99 (85%; 49 ± 11 years-old; 82% male) with occupational exposure to ionizing radiation and 18 (15%; 39 ± 12 years-old; 61% male) unexposed controls. The prevalence of overall cortical and posterior subcapsular lens changes (including subclinical findings) was higher in exposed participants compared with controls (47 vs. 17%, P = 0.015). Occupational exposure and age over 60 were independent predictors of lens changes (odds ratio [95% CI]: 6.07 [1.38–43.45] and 7.72 [1.60–43.34], respectively). The prevalence of frank opacities was low and similar between the two groups (14 vs. 6%, P = 0.461). Most lens findings consisted of subclinical changes in the periphery of the lens without impact on visual acuity. Conclusions: Compared with unexposed controls, ICs and cath-lab staff had a higher prevalence of lens changes that may be attributable to ionizing radiation exposure. While most of these changes were subclinical, they are important due to the potential to progress to clinical symptoms, highlighting the importance of minimizing staff radiation exposure.
KW - cataract
KW - catheterization
KW - lens
KW - occupational hazard
KW - radiation
UR - http://www.scopus.com/inward/record.url?scp=85023594389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85023594389&partnerID=8YFLogxK
U2 - 10.1002/ccd.27173
DO - 10.1002/ccd.27173
M3 - Article
C2 - 28707381
AN - SCOPUS:85023594389
SN - 1522-1946
VL - 91
SP - 647
EP - 654
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 4
ER -